SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
OpenAI Restricts Astra AI Over Cyberattack Risks 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
| Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) | ||
| Filing of the 2017 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report PARIS, France - March 7, 2018 - Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its "Document de Référence" containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). These documents are available on the "Investors" section of the company's corporate website (www.sanofi.com/en/investors/reports-and-publications). In addition, the Form 20-F is available on the website of the SEC (www.sec.gov) and the "Document de Référence" is available on the website of the AMF (www.amf-france.org). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request. | ||
| About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life | ||
| Media Relations Contact Laurence Bollack Tel.: +33 (0)1 53 77 46 46 [email protected] | Investor Relations Contact George Grofik Tel.: +33 (0)1 53 77 45 45 [email protected] | |
Attachment:
http://www.globenewswire.com/NewsRoom/AttachmentNg/6f36ccb1-cf99-4848-ab29-73e758e88168
